|
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Gynaecological
Centre SALUD Y MUJER ( HEALTH AND WOMAN) No. of patients: 22 with Papilloma Virus. All the patients responded well to the treatment with EPIGEN, which may be considered an effective ANTIVIRAL AGENT for the treatment of the Papilloma Virus in the external genital organs, vulva and vagina. No. of patients: 20 with Genital Herpes. Complete remission in 18 patients. The two remaining
cases are HIV positive. Gynaecological Centre
SALUD Y MUJER ( HEALTH AND WOMAN) No. of patients: 25 with Type I Herpes Simplex. Clinical effectiveness and tolerance. MOSCOW MEDICAL ACADEMY No. of patients: 30 with Herpes Simplex, Progenital Herpes, Recurrent Herpes and Herpes Zoster. High ANTIVIRAL effectiveness of the preparation
EPIGEN, together with good tolerance. HOSPITAL GENERAL DE MÉXICO No. of patients: 150 with Genital Herpes. We consider that treatment with EPIGEN
may be a good alternative for Genital Herpes as an initial infection (100%)
and as well in recurrent cases (90%). MINISTRY OF HEALTH No. of patients: 30 with genital herpes Improvement in 100 % of the treated cases (significant
improvement in 73.3 % of the cases and good improvement in 26.7 % of the
cases) MINISTRY OF PUBLIC
HEALTH No. of patients: 4 patients with genital herpes EPIGEN is an
effective new medicine for the treatment of the topical forms of genital
herpes, showing a quick clinical action and obtaining a durable remission. RUSSIAN MEDICAL STATE
UNIVERSITY No. of patients: 30 patients with urogenital herpes Good tolerance Prof. V. N. Prilepskaya No. of women patients: 18 with papilloma virus The preliminary conclusions of the clinical study
give evidence of the good results of EPIGEN to treat inflammation, with
analgesic and antiviral effects in patients with papilloma and herpes
virus. CENTRAL SCIENTIFIC
RESEARCH INSTITUTE No. of patients: 30 with papilloma virus Antiviral, immunomodulating and anti-inflammatory
actions |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||